Drug Designing

The field of structure-based drug design is a rapidly developing area in which many successes have occurred in recent years. The explosion of genomic, proteomic, and structural information has providing hundreds of new targets and opportunities for future drug lead discovery. This review summarizes the process of structure-based drug design and includes, primarily, the choice of a target, the evaluation of a organization of that target, the pivotal questions to consider in choosing a method for drug lead discovery, and evaluation of the drug leads. Key principles in the field of structure-based drug design will be explained through a case study that explores drug design for AmpC β-lactamase.

    Related Conference of Drug Designing

    July 03-05, 2017

    4th Annual Congress on Drug Discovery & Designing

    Bangkok, Thailand
    August 10-12, 2017

    8th Asian Biologics and Biosimilars Congress

    Beijing, China
    September 25-26, 2017(10 Plenary Forums- 1 Event)

    7th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR

    Chicago, Illinois, USA
    September 25-26, 2017
    (10 Plenary Forums - 1Event)

    6th International Summit on GMP, GCP & Quality Control

    Chicago, Illinois, USA
    October 02-04, 2017

    World Congress on Antibiotics: R&D, Market

    Atlanta, USA
    October 16-18, 2017

    11th World Drug Delivery Summit

    (10 Plenary Forums - 1Event)
    Baltimore, Maryland, USA
    October 16-17, 2017

    10th International Conference and Exhibition on Biologics and Biosimilars

    San Francisco, California,USA
    November 16-17, 2017

    4th European Biopharma Congress

    Vienna, Austria
    Dec 14-16, 2017

    7th Global Mass Spectrometry Congress

    Dubai, UAE

    Drug Designing Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in